anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical field of microorganisms, and particularly relates to lactobacillus delbrueckii subspecies bulgaricus, a microbial inoculum containing the same and application thereof. The preservation number of the Lactobacillus delbrueckii subspecies bulgaricus is CGMCC No. 21396. The preparation method of the microbial inoculum comprises the following steps: activating lactobacillus delbrueckii subspecies bulgaricus to obtain activated thalli, inoculating the activated thalli into a fermentation culture medium for fermentation to obtain fermentation liquor; and (3) carrying out solid-liquid separation on the fermentation liquor to obtain thalli, carrying out heavy suspension on the thalli, crushing and extracting, and carrying out solid-liquid separation on the thalli to obtain an extracting solution. The invention also provides application of the lactobacillus delbrueckii subsp bulgaricus in preparing food and/or medicines for preventing acute alcoholic liver injury and/or improving the composition structure of intestinal flora. The Lactobacillus delbrueckii subspecies bulgaricus has good oxidation resistance, and can regulate intestinal flora and prevent or relieve alcoholic liver injury.
As required for urologic irrigation.

0.25% Acetic Acid Irrigation USP may be administered by gravity drip via an administration set connected to an indwelling urethral catheter designed for continuous or intermittent two-way flow.

For continuous or intermittent irrigation, the rate of administration will correspond roughly to the rate of urine flow and should be adjusted to maintain a urinary effluent pH of 4.5 to 5.0.

Nitrazine or other pH paper may be used to monitor pH, preferably at least four times daily. Drip rate should be adjusted as necessary to maintain desired pH; increasing flow rate reduces pH value and vice versa. With continuous or intermittent irrigation, each patient will require a volume of approximately 500 to 1500 mL per 24 hours.

Some additives may be incompatible. Consult with pharmacist. When introducing additives, use aseptic techniques. Mix thoroughly. Do not store.

This drug product should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
PURPOSE: comparison between two anesthetic techniques on the ability to reduce pain during panretinal photocoagulation (PRP) treatment.
METHODS: Observational retrospective single center study. Medical charts of patients who underwent PRP for proliferative diabetic retinopathy were revised. Patients were included if they had the first eye treated with oxybuprocaine hydrochloride drops, and in case of severe pain, the fellow eye received topical anesthesia in combination with 2% subconjunctival lidocaine. The groups were compared for pain perception using an analog visual scale (VAS), number of laser spots, number of interruptions, and laser session duration.
RESULTS: Forty-two eyes of 21 patients (mean age: 58.3 ± 7.6 years) were analyzed. The mean number of laser spots was significantly higher under combined anesthesia (+84.2 ± 155.9 spots, p = 0.01), with a reduced time for laser execution (-2.5 ± 3.12, p = 0.0008). The use of combined anesthesia significantly decreased the number of interruptions (-40.8%, p < 0.0001) into a single session. On the pain grading scale, the pain perception was significantly lower in the combined anesthesia group (p < 0.0001). In eyes receiving topical anesthesia the treatment was stopped for pain in 5 eyes (23.8%), while 5 eyes under combined anesthesia presented subconjunctival hemorrhage (23.8%).
CONCLUSION: Using combined anesthesia in patients subjected to PRP appeared to reduce pain perception limiting the treatment duration and the interruptions for pain without significant complications. Further studies on a larger scale would be desirable to replicate such findings and standardize the analgesic procedures in ophthalmology.
Dynamic Contrast Enhanced Magnetic Resonance (MR) Lymphangiogram and heavy T2 Magnetic Resonance imaging data will be evaluated for abnormal lymphatic perfusion of the lung parenchyma. Abdominal and thoracic lymphatic malformations will be characterized by location, number, size, relationship to other organs and perfusion patterns in order to create a basis of imaging classification of lymphatic abnormalities (LA). Subjects will undergo both Dynamic Contrast Enhanced Magnetic Resonance Lymphangiogram (DCMRL) and Heavy Weighted T2 Imaging.
Healthy participants will receive single ascending doses of GSK3923868 or placebo in the planned treatment sequence: GSK3923868 50 mcg/100 mcg/Placebo in treatment periods 1, 2 and 3 respectively. There will be at least 10 days of wash-out period between doses for each participant.
PURPOSE:To produce the titled microcapsule in high trapping yield of principal drug, by producing a W/O-type emulsion from an oily layer containing a polymer and an aqueous layer containing a specific amount of encephalin, mixing the emulsion with an aqueous solution of a dispersing agent and distilling out the solvent from the resultant emulsion. CONSTITUTION:A W/O-type emulsion is produced from (A) an oily phase containing a polymer having bio-compatibility and hardly soluble or insoluble in water, preferably a polymer having acidic residue (e.g. a polylactic acid, a copolymer of lactic acid and glycolic acid, etc.) and (B) an aqueous layer containing 5-20wt%, preferably 5.0-15.0wt% (based on the polymer) encephalin, its analog or its salt with a weak acid having a pKa of >=4.0, preferably 4.0-9.5 (e.g. acetic acid, propionic acid, etc.). The obtained W/O-type emulsion is mixed with an aqueous solution of a dispersing agent to form a W/O/W-type emulsion. A microcapsule having tough wall membrane effective in suppressing excessive initial release of the content can be produced by distilling the oily layer solvent from the obtained emulsion.
Teeth are vulnerable to structural compromise, primarily attributed to carious lesions, in which microorganisms originating from the oral cavity deteriorate the mineralized structures of enamel and dentin, subsequently infiltrating the underlying soft connective tissue, known as the dental pulp. Nonetheless, dental pulp possesses the necessary capabilities to detect and defend against bacteria and their by-products, using a variety of intricate defense mechanisms. The pulp houses specialized cells known as odontoblasts, which encounter harmful substances produced by oral bacteria. These cells identify pathogens at an early stage and commence the immune system response. As bacteria approach the pulp, various cell types within the pulp, such as different immune cells, stem cells, fibroblasts, as well as neuronal and vascular networks, contribute a range of defense mechanisms. Therefore, the immune system is present in the healthy pulp to restrain the initial spread of pathogens, and then in the inflamed pulp, it prepares the conditions for necrosis or regeneration, so inflammatory response mechanisms play a critical role in maintaining tissue homeostasis. This review aims to consolidate the existing literature on the immune system in dental pulp, encompassing current knowledge on this topic that explains the diverse mechanisms of recognition and defense against pathogens exhibited by dental pulp cells, elucidates the mechanisms of innate and adaptive immunity in inflamed pulp, and highlights the difference between inflamed and normal pulp tissue.
This study was designed to evaluate the effect of azithromycin on the incidence of febrile morbidity after the emergency cesarean section. The standard antimicrobial prophylaxis which is recommended by the ACOG is the 1st generation cephalosporin intravenously only but some of the bacteria that can cause the febrile morbidity after cesarean section wouldn't be killed by the 1st generation cephalosporin. The antibiotic that can cover them is macrolide group antibiotic such as azithromycin. Therefore this study will compare the regimen of standard antimicrobial prophylaxis and the regimen of standard antimicrobial prophylaxis with azithromycin intravenously in preventing the febrile morbidity after emergency cesarean section. Control group will receive the 1st generation cephalosporin intravenously and the intervention group will receive the 1st generation cephalosporin with azithromycin 500mg intravenously. Primary outcome is febrile morbidity which assessed at postoperative day 3. The definition of the febrile morbidity in this study is including surgical site infection, endometritis, urinary tract infection and fever alone. Secondary outcomes are febrile morbidity at postoperative day 7 and day30, neonatal outcome and adverse effect from azithromycin use.
Keratoplasty is gaining popularity worldwide as a method of controlling myopia progression. Several clinical studies have shown that overnight wear of Orthokeratology lenses (OK) is an effective method of slowing myopia progression in adolescents.However, wearing corneal contact lenses tends to interfere with tear homeostasis, which may lead to ocular discomfort, dryness, and ocular surface disorders. More than 50% of contact lens wearers report symptoms of dry eye.Prolonged contact with the cornea can have an effect on the corneal layer.With the rapid increase in the use of OK lenses worldwide, potential complications have become a major concern for parents. Potential complications include keratitis and corneal epithelial damage. In addition, overnight OK lens wear has been associated with decreased tear production and reduced tear film stability. Recently, a four-week study by Carracedo et al. demonstrated that OK lens wear did not significantly change fluorescein-stained tear film breakup time or Schirmer's test I results, but subjects had increased dry eye symptoms one month after wear Decrease in cupped cell density.

Diquafosol Ophthalmic Solution (DQS) is a potent purinergic P2Y2 receptor agonist, a stabilized synthetic derivative of the naturally-occurring nucleotide uridine 5'-triphosphate; it stimulates the secretion of mucin and tears by conjunctival cup cells and conjunctival epithelial cells. Several studies have shown that Diquafosol sodium is effective in the treatment of dry eye. In addition, some studies have shown that Diquafosol sodium eye drops have significantly alleviated dry eye symptoms and improved ocular surface parameters in children wearing keratomileusis lenses at night. However, the available research lacks the ability of the DQS to assess the effect of DQS on visual acuity and quality of life improvement in patients with dry eye after wearing OK lenses. The results would inform clinicians to improve comfort and compliance with keratoplasty lenses in adolescents.
Psoriasis is a chronic non-contagious autoimmune disease. Gallic acid is a natural compound with potential health benefits, including antioxidant, anticancer, antiviral and antibacterial properties. Nevertheless, the influence of gallic acid on psoriasis has not been fully determined. This investigation aimed to discover the effect of gallic acid on psoriasis. Thirty-one pairs of psoriatic skin tissues and healthy adult human skin tissues were collected. Human keratinocytes (HaCaT cells) were transfected with interleukin 17A (IL-17A) to create the psoriatic keratinocyte model. The content of bromodomain-containing protein 4 (BRD4) microRNA was assessed using qRT-PCR testing. The content of BRD4 was detected by Western blotting. Cell migration was evaluated by conducting a wound healing assay. Cell proliferation was determined using an EdU assay. Apoptosis was detected by the TUNEL assay. The contents of interferon gamma (IFN-γ), IL-6, IL-8 and IL-17 were detected by ELISA. BRD4 was up-regulated in psoriatic skin tissues and in the IL-17A group compared to the healthy adult human skin tissues and the control group. Silencing BRD4 inhibited cell migration, proliferation and inflammatory response but induced apoptosis in IL-17A-treated HaCaT cells. Conversely, BRD4 over-expression promoted cell migration, proliferation and inflammatory response but suppressed apoptosis in IL-17A-treated HaCaT cells. Gallic acid repressed cell migration, proliferation and inflammatory response but indu-ced apoptosis in HaCaT cells transfected with IL-17A by down-regulating BRD4. Gallic acid represses cell migration, proliferation and inflammatory response but induces apoptosis in IL-17A-transfected HaCaT cells by down-regulating BRD4.
* Cardiopulmonary arrest and/or sudden death occurred in 3.0% of patients treated with PORTRAZZA in combination with gemcitabine and cisplatin. Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, with aggressive replacement when warranted during and after PORTRAZZA administration [see Warnings and Precautions (5.1, 5.2)]. 
  * Hypomagnesemia occurred in 83% of patients receiving PORTRAZZA in combination with gemcitabine and cisplatin, and was severe in 20% of patients. Monitor patients for hypomagnesemia, hypocalcemia, and hypokalemia prior to each dose of PORTRAZZA during treatment and for at least 8 weeks following completion of PORTRAZZA. Withhold PORTRAZZA for Grade 3 or 4 electrolyte abnormalities. Replete electrolytes as medically appropriate [see Warnings and Precautions (5.2)].
The present invention relates to an externally applied ointment for treating burns and scalds, which belongs to the technical field of traditional Chinese medicine and has the advantages of rapid therapeutic effect and reliable effect. The present invention overcomes the disadvantages of bad therapeutic effect of common medicine in general hospitals and slow healing. For treating second-degree burns and scalds and third-degree burns and scalds, the skin grafting is not needed. The externally applied ointment of the present invention is prepared from the following raw materials: tuber of hyacinth bletilla, arnebia root, milkvetch root, angelica, pubescent holly root, hiraute shiny bugleweed herb, olibanum, myrrh, coptis, baical skullcap root, weeping forsythia capsule, dandelion, rhizoma corydalis, borneol, beeswax and sesame oil. The raw materials are processed into ointment in a specific method. Under general situation, the first-degree burn and scald can be healed in 1 to 2 days after the ointment is used; the superficial second-degree burn can be healed within 4 to 6 days; the deep second-degree burn can be healed within 10 to 20 days; the third-degree burn can be healed within 40 to 60 days; the specific healing time is determined by the size of wound surface and the timeliness extent of therapy.
Atherosclerotic plaques are fatty deposits that form in the walls of major arteries and are one of the major causes of heart attacks and strokes. Macrophages are the main immune cells in plaques and macrophage dynamics influence whether plaques grow or regress. Macrophage proliferation is a key process in atherosclerosis, particularly in the development of mid-stage plaques, but very few mathematical models include proliferation. In this paper we reframe the lipid-structured model of Ford et al. (J Theor Biol 479:48-63, 2019. https://doi.org/10.1016/j.jtbi.2019.07.003 ) to account for macrophage proliferation. Proliferation is modelled as a non-local decrease in the lipid structural variable. Steady state analysis indicates that proliferation assists in reducing eventual necrotic core lipid content and spreads the lipid load of the macrophage population amongst the cells. The contribution of plaque macrophages from proliferation relative to recruitment from the bloodstream is also examined. The model suggests that a more proliferative plaque differs from an equivalent (defined as having the same lipid content and cell numbers) recruitment-dominant plaque in the way lipid is distributed amongst the macrophages. The macrophage lipid distribution of an equivalent proliferation-dominant plaque is less skewed and exhibits a local maximum near the endogenous lipid content.
<P>PROBLEM TO BE SOLVED: To provide a material which blocks ultraviolet rays in both of an ultraviolet A range of 320-380 nm wavelength and an ultraviolet B range of 290-320 nm wavelength and has high visible light transmittance.  <P>SOLUTION: Fusiform titanium oxide particles are incorporated into zinc oxide particles having an average particle diameter of 0.01-1.0 μm. The fusiform titanium oxide particles preferably have an average major axis diameter of 0.005-0.5 μm and are preferably incorporated into interiors and/or surfaces of the zinc oxide particles. A zinc compound and an alkali compound are mixed in the presence of a fusiform titanium oxide and the zinc compound is neutralized, thereby objective zinc oxide is produced. This zinc oxide is suitable for use in an ultraviolet shielding composition, particularly sunscreen cosmetics.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Danish National Health Survey (DNHS): This cohort included 177 639 persons aged 16 years and older randomly selected across Denmark who answered a questionnaire in 2010 or 2013.40 Information on age, sex, education and labor market affiliation was obtained from national registers. The questionnaire focused on sex, age, cohabiting status, education, occupation, smoking, alcohol consumption, diet, physical activity and anthropometric data.
The invention belongs to the technical field of health-care products, and especially relates to fast-effect stomach-invigorating capsules. The capsules provided by the invention are prepared from the raw materials of, by weight, 10-20 parts of raw rehmannia rhizome, 10-25 parts of ginger, 10-25 parts of garlic, 10-25 parts of medlar, 10-20 parts of licorice root, and 15-30 parts of egg membrane. According to the invention, a traditional Chinese medicine raw rehmannia rhizome is adopted, and auxiliary materials such as ginger and egg membrane are adopted, such that symptoms of gastritis patients can be greatly alleviated. The product is prepared into capsules, such that the product can be taken by various gastritis patients, and can provide a taste better than that of traditional Chinese medicine pellets. Therefore, the capsules are acceptable. The capsules have functions such as stomach nourishing and stomach invigorating. The preparation raw materials of the capsules have no toxic or side effect. The process is simple and reasonable, the cost is low, and the capsules are safe and reliable. According to the invention, no added device is needed, and production can be carried out by various health-care product factories, pharmaceutical factories, or capsule production factories. The capsules are suitable for large-scale productions of pharmacy-related enterprises, and have good market prospect.
The present invention relates to a composite series medicament of zanthoxylum seed kernel oil and Chuanxiong alkoloid and a preparation technology thereof, and provides series preparations of oral liquor, tablets and capsules for treating cardio-cerebrovascular diseases. The composite series medicament is mainly composed of zanthoxylum seed kernel oil and chuanxiong alkaloid. In the preparation technology, the zanthoxylum seeds adopt a zanthoxylum seed kernel oil separated preparation technology and a low-temperature separation, filtration and purification technology, and thus, medicinal zanthoxylum seed kernel oil is prepared. Thick paste or dry powder of chuanxiong alkaloid is extracted out of chuanxiong by a steam distillation method and a water alcohol method. The zanthoxylum seed kernel oil and the chuanxiong alkaloid are compounded. Thus, a series of Chinese patent medicines are prepared in bulk. The composite series medicament has the advantages of scientific preparation technology, cheap production cost, effective recipe, reasonable compatibility, and stable content, takes effect at quick efficiency, slow efficiency and gentle efficiency by times, and has obvious complementary action. The series of preparations can be used in a selection way, and have significant curative effects on cardio-cerebrovascular diseases in the primary period, treatment period and recovery period.
Studies examining the carcinogenic potential of pomalidomide have not been conducted. One of 12 monkeys dosed with 1 mg/kg of pomalidomide (an exposure approximately 15-fold of the exposure in patients at the recommended dose of 4 mg/day) developed acute myeloid leukemia in a 9-month repeat-dose toxicology study.

Pomalidomide was not mutagenic or clastogenic in a battery of tests, including the bacteria reverse mutation assay (Ames test), the in vitro assay using human peripheral blood lymphocytes, and the micronucleus test in orally treated rats administered doses up to 2000 mg/kg/day.

In a fertility and early embryonic development study in rats, drug-treated males were mated with untreated or treated females. Pomalidomide was administered to males and females at doses of 25 to 1000 mg/kg/day. When treated males were mated with treated females, there was an increase in post-implantation loss and a decrease in mean number of viable embryos at all dose levels. There were no other effects on reproductive functions or the number of pregnancies. The lowest dose tested in animals resulted in an exposure (AUC) approximately 100-fold of the exposure in patients at the recommended dose of 4 mg/day. When treated males in this study were mated with untreated females, all uterine parameters were comparable to the controls. Based on these results, the observed effects were attributed to the treatment of females.
The present invention provides one or more immunogenic polypeptides for use in a preventive or therapeutic vaccine against latent or active infection in a human or animal caused by a Mycobacterium species, e.g. Mycobacterium avium subsp. paratuberculosis. Furthermore a single or multi-phase vaccine comprising the one or more immunogenic polypeptides is provided for administration for the prevention or treatment of infection with a Mycobacterium species, e.g. Mycobacterium avium subsp. paratuberculosis. Additionally, nucleic acid vaccines, capable of in vivo expression of the multi-phase vaccine comprising the one or more immunogenic polypeptides, is provided for prevention or treatment of infection with a Mycobacterium species, e.g. Mycobacterium avium subsp. paratuberculosis.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, yet the cellular and molecular mechanisms underlying the AF substrate remain unclear. Isolevuglandins (IsoLGs) are highly reactive lipid dicarbonyl products that mediate oxidative stress-related injury. In murine hypertension, the lipid dicarbonyl scavenger 2-hydroxybenzylamine (2-HOBA) reduced IsoLGs and AF susceptibility. We hypothesized that IsoLGs mediate detrimental pathophysiologic effects in atrial cardiomyocytes that promote the AF substrate. Using Seahorse XFp extracellular flux analysis and a luminescence assay, IsoLG exposure suppressed intracellular ATP production in atrial HL-1 cardiomyocytes. IsoLGs caused mitochondrial dysfunction, with reduced mitochondrial membrane potential, increased mitochondrial reactive oxygen species (ROS) with protein carbonylation, and mitochondrial DNA damage. Moreover, they generated cytosolic preamyloid oligomers previously shown to cause similar detrimental effects in atrial cells. In mouse atrial and HL-1 cells, patch clamp experiments demonstrated that IsoLGs rapidly altered action potentials (AP), implying a direct effect independent of oligomer formation by reducing the maximum Phase 0 upstroke slope and shortening AP duration due to ionic current modifications. IsoLG-mediated mitochondrial and electrophysiologic abnormalities were blunted or totally prevented by 2-HOBA. These findings identify IsoLGs as novel mediators of oxidative stress-dependent atrial pathophysiology and support the investigation of dicarbonyl scavengers as a novel therapeutic approach to prevent AF.